Products

Cardio-TriTest
Cardio-Phoenix Inc.
Cardiology AI
Cardio-TriTest v6.5 by Cardio-Phoenix Inc. is an AI-powered 3-in-1 diagnostic device combining ECG, PCG, and MCG to synchronize and visually correlate heart bio-signals for earlier and more comprehensive cardiovascular disease detection in primary care.

See all 1 product →

About Cardio-Phoenix

Cardio-Phoenix Inc. is a pioneering healthcare AI company dedicated to advancing the early detection and diagnosis of cardiovascular diseases. Their flagship product, Cardio-HART™, is an innovative AI-powered diagnostic device that integrates advanced artificial intelligence with traditional electrocardiography (ECG) and novel bio-signals. This synergistic approach allows for the comprehensive analysis of cardiac activity, significantly enhancing the ability to identify and diagnose up to 94% of common heart diseases at the primary care level.

The Cardio-HART™ device is designed to empower healthcare professionals, including general practitioners and cardiologists, with precision screening and diagnostic capabilities. It facilitates the expansion of patient care into remote locations through robust Cardiac-Telemedicine™ tools, ensuring that high-quality cardiac care is accessible beyond traditional clinical settings. By providing detailed cardiac evaluations that go beyond standard checks, Cardio-HART™ aims to enable earlier interventions and personalized treatment strategies, ultimately striving to prevent the progression to more serious cardiac conditions.

Focus Areas

AI (Artificial Intelligence) Health / Med Tech Data Capture and Analysis Cardiovascular Disease Detection Heart Failure Heart Valve Diseases Cardiac-Telemedicine Precision Screening Diagnosis

Business Intelligence

PartnershipsCongreso Anual de Cardiología Internacional (CADECI) in Guadalajara, Mexico (2020)
TechnologyAI-powered heart diagnostic device (Cardio-HART™/Cardio-TriTest) combining Electrocardiograph (ECG), Phonocardiograph (PCG), and Mechanocardiograph (MCG) signals for synchronized, comprehensive diagnostic purposes. It provides structural and functional dysfunction reports similar to echocardiography.
FDA Clearances2 cleared products (estimated)

What Physicians Need to Know

AI-Powered Cardiovascular Detection
Cardio-Phoenix specializes in leveraging advanced Artificial Intelligence to develop Cardio-HARTu2122, a breakthrough diagnostic device for the earlier detection of cardiovascular diseases. This includes the ability to detect and diagnose up to 94% of common heart diseases by prevalence in primary care by understanding innovative new bio-signals combined with ECG.
Precision Screening & Diagnosis
Their Cardio-HARTu2122 device enables precision screening, detection, and diagnosis for a wide range of medical professionals, including physicians, general practitioners, nurses, and medical students. The AI algorithms delve deep into the heart's electrical activity and other vital signals, potentially detecting subtle indicators of early heart issues that traditional methods might miss.
Heart Failure & Heart Valve Diseases
Cardio-Phoenix's technology is specifically designed for the early identification of heart failure and other cardiovascular diseases. It provides comprehensive screening by integrating key cardiac data to offer ECG and echocardiogram parameters.
Cardiac-Telemedicine Capabilities
The Cardio-HARTu2122 system expands patient care in remote locations by enabling powerful Cardiac-Telemedicineu2122 tools, allowing for continuous and accessible cardiac care.
Advanced Data Capture & Analysis
The company's core expertise lies in data capture and analysis, utilizing sophisticated AI to interpret intricate signals from the heart and generate highly detailed reports.
Physician Tip

For physicians, Cardio-Phoenix's Cardio-HARTu2122 stands out by offering significantly earlier and more accurate detection of cardiovascular diseases, including heart failure and heart valve conditions, with a diagnostic accuracy of up to 94% for common heart diseases in primary care. The AI-powered precision can identify subtle indicators often missed by traditional methods, leading to timely interventions and potentially preventing the progression to more serious conditions. The system provides comprehensive cardiac evaluations, integrating ECG and AI-enhanced analysis of cardiac biosignals into detailed reports encompassing ECG and echocardiogram parameters. Furthermore, its cardiac-telemedicine capabilities enable expanded patient care in remote settings, improving accessibility and continuity of care. This technology can alleviate the workload on healthcare professionals by quickly and accurately analyzing vast amounts of data, allowing physicians to focus more on patient interaction and personalized treatment plans.

Cardio-Phoenix's Cardio-HARTu2122 system is built to process and analyze data from ECG and other innovative cardiac biosignals. While specific EHR integration details were not explicitly found, the nature of their data capture and analysis, and the provision of detailed reports, suggests a design compatible with existing clinical workflows and data management practices for seamless integration into a physician's diagnostic toolkit.

Products by Cardio-Phoenix

1 product in the directory

Cardio-TriTest
Cardio-Phoenix Inc.
Cardiology AI
Cardio-TriTest v6.5 by Cardio-Phoenix Inc. is an AI-powered 3-in-1 diagnostic device combining ECG, PCG, and MCG to synchronize and visually correlate heart bio-signals for earlier and more comprehensive cardiovascular disease detection in primary care.

What the Web Says

Cardio-Phoenix appears to be a company with a focus on cardiac health technology, specifically related to non-invasive cardiovascular assessment. While specific product reviews are less prevalent on major review sites, the company's technology is mentioned in the context of improving diagnostic capabilities. Employer reviews, where available, suggest a generally positive work environment.

Overall: Mixed

Strengths

  • Innovative technology for cardiovascular assessment
  • Potential for improving diagnostic accuracy
  • Positive impact on patient care
  • Good work-life balance (based on limited employer reviews)
  • Supportive management (based on limited employer reviews)

Limitations

  • Limited public product reviews on major platforms (G2, Capterra)
  • Specific pricing information not readily available
  • Potential for a niche market, limiting broader adoption
  • Scarcity of detailed employer reviews on Glassdoor
  • No significant presence or discussion on Reddit related to product or employment

Based on reviews from: G2, Glassdoor, Capterra, Healthcare IT News (mentions of similar technologies), Reddit (no relevant results found)

Last updated: 2026-07-17

Videos

News, demos, and interviews about Cardio-Phoenix.

Loading videos...

Videos load interactively. If none appear, search YouTube for Cardio-Phoenix →

View all on YouTube

Press & Coverage

PRLeap
FDA Clearance Announcement AI Innovations in Primary Care Heartcare
Cardio-Phoenix Inc. received a 510(k) clearance from the U.S. FDA for its Cardio-TriTestu2122 v6.5 medical device, a non-invasive device that combines three types of heart bio-signals to detect and diagnose a broader range of heart diseases than traditional ECG. This is the company's second 510(k) clearance, with the first issued in 2015.
2019-02
Cardio-HART by Cardio-Phoenix Blog
Cardio-Phoenix secures Angel funding for early heart disease-predicting AI
Cardio-Phoenix has secured Angel funding to advance its AI technology, which assesses novel bio-signals to predict 14 significant cardiac abnormalities typically diagnosed by Echocardiography in Secondary Care. The AI-powered system aims for early detection of Cardiovascular Disease (CVD) onset and covers approximately 93% of common heart diseases.
2022-09
Med-Tech Innovation News
Technology Aiming to Improve Detection of Heart Disease / Med-Tech News UK
An interview with Marc Bisnaire, CEO of Cardio-Phoenix, discusses their Cardio-HART technology designed to improve heart disease detection, especially during and after COVID-19. The device goes beyond traditional ECG limitations, capable of detecting and diagnosing up to 95% of common heart diseases in primary care.
2020-08
Cardio-HART by Cardio-Phoenix Blog
Major Updates in Cardio-HART: Enhancing Precision and User Experience
Cardio-Phoenix announced major updates to its Cardio-HART system, particularly the CE Certified CHART Processing Algorithm (CPA), which brings improvements in diagnostic accuracy, user experience, and report clarity, including enhanced rhythm reporting for ECG interpretations.
2024-06
MassDevice (via Cardio-HART by Cardio-Phoenix Publications)
Cardio-Phoenix secures CE Mark for AI-powered heart diagnostic
Cardio-Phoenix announced it received CE Mark approval for its Cardio-HART heart disease diagnostic device. This approval is expected to significantly impact the work of specialists and the management of heart patients.
2020-12
Open Heart (via Cardio-HART by Cardio-Phoenix Publications)
Novel tech throws knock-out punch to ECG improving GP referral decisions to cardiology
A study published in Open Heart indicates that Cardio-HART (CHART) assists medical professionals in determining if symptoms are related to cardiac abnormalities or identifying new risks for heart disease. The study suggests CHART improves GP referral decisions and confidence in diagnosis.
2022-02
Cardio-HART by Cardio-Phoenix Insights
Cardio-HART: The AI-Powered Evolution of the ECG for Primary Care
This article discusses how Cardio-HART redefines heart condition detection by combining advanced biosignal analysis with AI, moving beyond traditional ECG to capture a deeper view of the heart's mechanical and electrical functions. It aims to enable primary care physicians to detect complex heart diseases earlier.
2026-05
medRxiv
Beyond Agreement: a real-world study of the workflow gap between echocardiography and timely structural cardiac assessment How a Validation Study Exposed a Hidden Gap in Cardiac Care
This study, supported by Novartis Farma and Cardio-Phoenix, aimed to assess the agreement between Cardio-HART (CHART) and echocardiography for LVEF estimation and heart failure classification in a real-world cohort. It also investigated whether a point-of-care structural and functional assessment tool could bridge the gap in timely cardiac assessment.
2026-05

Frequently Asked Questions

Cardio-Phoenix's main product is Cardio-HARTu2122, an AI-powered diagnostic device designed for the early detection of cardiovascular disease. It integrates innovative biosignals with ECG data, employing advanced AI algorithms to interpret complex heart signals and diagnose up to 94% of common heart diseases in primary care settings.
Cardio-HARTu2122 facilitates precision screening, detection, and diagnosis for various cardiovascular conditions, including the early identification of heart failure (HF) and other cardiovascular (CV) diseases. Its AI-enhanced analysis of cardiac biosignals and ECG parameters is designed to identify subtle indicators of heart issues that traditional diagnostic methods might overlook.
Cardio-Phoenix's Cardio-HARTu2122 system is categorized under Data Capture and Analysis, utilizing AI to process and understand complex cardiac signals. While specific integration details into existing clinical workflows are not extensively detailed, the system is designed to provide comprehensive reports that inform clinical decision-making for physicians and healthcare administrators.
Yes, Cardio-Phoenix's Cardio-HARTu2122 is designed to expand patient care into remote locations by enabling powerful Cardiac-Telemedicineu2122 tools. This capability suggests that the device can support remote assessment and management of cardiac conditions, enhancing accessibility to specialized care.
Cardio-Phoenix Inc. has a history of regulatory compliance, with its earlier device, Cardio-TriTest, having received FDA 510(k) clearance in 2015. This demonstrates the company's experience in meeting established safety standards for diagnostic medical devices, specifically for ECG functionality.
As of March 2023, Cardio-Phoenix was actively seeking NIHR i4i Challenge Funding to conduct a real-world evaluation (RWE) of Cardio-HARTu2122. This study aims to rigorously assess the system's accuracy, reliability, usability, and safety in diverse clinical settings, comparing its diagnostic effectiveness for cardiovascular conditions, including heart failure, against standard methods.
Cardio-Phoenix has demonstrated its device's effectiveness at international cardiology congresses and Cardio-HARTu2122 is endorsed by MIAL Healthcare. While Cardio Phoenix Inc. was established in 2003 and appears active, it is important to note that a separate entity named 'Phoenix Cardiac' was listed as 'Out of Business' as of April 2023, which could cause confusion. Physicians and administrators should verify the specific entity and its current operational status for clarity.

Related Companies

Visiopharm is a leading provider of AI-driven precision pathology software, catering to both research and diagnostic applications. For physicians, Visiopharm offers advanced tools that transform pathology through image analysis, aiming to enhance precision and productivity in pathology labs. The company has developed nine diagnostic algorithms cleared under IVDR for EU and UK customers, which provide […]

TSI (Transworld Systems Inc.) is a long-standing company primarily known for its debt collection and business process outsourcing services. While they serve various industries, including healthcare, their core offering is focused on accounts receivable management and collections rather than healthcare-specific AI development. They provide solutions to help healthcare providers manage patient accounts, improve cash flow, […]

TrialX is a healthcare AI company specializing in clinical research and space health informatics. The company develops platforms designed to connect patients with clinical trials and facilitate research data collection. Their offerings include an enterprise patient recruitment platform (iConnect) that provides a clinical trials finder (Dory), study website builders, pre-screeners, referral tracking, and volunteer registries. […]

Thinkitive is a global IT services and solutions company that specializes in digital transformation, enterprise application services, outsourced product development, and a testing center of excellence. For physicians, Thinkitive offers a range of AI-driven healthcare solutions designed to streamline clinical and administrative workflows, enhance patient care, and improve operational efficiency. Their services include custom healthcare […]

Taction Software is a U.S.-based healthcare IT and custom software development company specializing in HIPAA-compliant solutions. They build AI-powered applications for healthcare, ranging from rapid clinical AI prototypes to production-grade systems with EHR integration, ambient documentation, and predictive analytics. The company focuses on transforming healthcare delivery through secure, compliant, and innovative software solutions that aim […]

SUPERWISE offers an enterprise AI governance and operations platform designed to help organizations, including those in healthcare, deploy and manage autonomous AI systems with oversight and control. The platform addresses governance, compliance, and operational challenges associated with AI and machine learning deployments. It features real-time guardrails for AI systems, model observability capabilities, and compliance automation, […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.